<DOC>
	<DOCNO>NCT00098865</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth tumor cell stop blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop tumor cell divide stop grow die . Combining thalidomide temozolomide may kill tumor cell . PURPOSE : This phase II trial study effectiveness combine thalidomide temozolomide treat young patient relapse progressive brain tumor recurrent neuroblastoma .</brief_summary>
	<brief_title>Thalidomide Temozolomide Relapsed Progressive CNS Disease Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility thalidomide temozolomide pediatric patient relapse progressive poor prognosis brain tumor recurrent neuroblastomas . Secondary - Determine preliminarily evidence biologic activity regimen patient . - Determine toxic effect regimen patient . STATISTICAL DESIGN : The primary data analysis estimate percentage patient complete 6 month therapy mixed population . With target accrual 20 patient 90 % confidence true feasibility rate wider 40 % .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* diagnosis 1 following : Poor prognosis brain tumor Relapsed progressive disease No curative therapy exist Neuroblastoma Recurrent disease NOTE : *Histologic confirmation require brain stem glioma ; patient brain stem glioma must clinical radiographic evidence disease Patients brain stem glioma must symptoms last &lt; 3 month comprise cranial nerve deficit ( often VI VII ) and/or ataxia and/or long tract sign PATIENT CHARACTERISTICS : Age 21 Performance status Karnofsky 50100 % OR Lansky 50100 % Life expectancy More 2 month Hematopoietic Hemoglobin ≥ 9.0 g/dL Platelet count &gt; 75,000/mm^3 WBC &gt; 2,000/mm^3 Absolute neutrophil count &gt; 1,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL SGOT SGPT ≤ 2 time normal ( SGOT ≤ 4 time normal patient take Zantac ) Alkaline phosphatase ≤ 2 time normal No active hepatic disease ≥ grade 3 Renal Creatinine &lt; 1.5 mg/dL OR Creatinine clearance ≥ 70 mL/min No active renal disease ≥ grade 3 Cardiovascular No active cardiac disease ≥ grade 3 Pulmonary No active pulmonary disease ≥ grade 3 Other Not pregnant nursing Fertile patient must use effective contraception 4 week study participation Willing able participate System Thalidomide Education Prescription Safety ( S.T.E.P.S.^® ) program No active psychiatric disease ≥ grade 3 PRIOR CONCURRENT THERAPY : Biologic therapy Prior biologic therapy allow No prior thalidomide Chemotherapy Prior chemotherapy allow No prior temozolomide Endocrine therapy Concurrent steroid allow Radiotherapy Prior radiotherapy allow Surgery Prior surgery allow Other Concurrent antiseizure medication allow No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>